The present disclosure provides a method of treating cutaneous T cell lymphoma (CTCL), in particular mycosis fungoides and/or Sézary syndrome, comprising administering a therapeutically effective amount of an antagonist antibody or binding fragment thereof specific to the IL-13 receptor to a patient in need thereof.
